Business Wire

AutoAir 5G Connected and Autonomous Vehicle Test Bed Goes Live

Share

The Airspan led 5G for Connected and Autonomous Vehicles (CAVs) consortium, AutoAir, has made huge strides at the Millbrook Proving Grounds test track this week.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190213005837/en/

(Photo: Business Wire)

(Photo: Business Wire)

The consortium announced final deployment of a Hyper-Dense small cell network of 89 base stations operating in the in the 2.3 and 3.4-3.8 GHz mid-band spectrum, including a 22 sector high-speed mobility 57-71 GHz mmWave highway system, delivering 5 Gbit/s every 300m. The live public demonstrations showed the system delivering greater than 1 Gbit/s capacity to a McLaren sports car while travelling at 160 mph on the Millbrook high-speed bowl with handovers occurring every 2 seconds. Real-time Telemetry was provided by McLaren’s Altas system.

A second demonstration showed real-time video streaming between multiple vehicles (each with four 4K cameras). The video was streamed between a range of different passenger cars, coaches and emergency vehicles which included police cars, fire trucks and ambulances.

These important achievements are fundamental steps towards enabling the key 5G use cases for CAVs. The AutoAir test bed at Millbrook can also directly contribute to 5G in other adjacent sectors such as Rail Transportation.

Eric Stonestrom, CEO of Airspan Networks said:

“Densification is key to making continuous 5G connectivity a reality, and we’re very proud of what we have accomplished with our partners.”

Paul Senior, CSO of Airspan Networks and CEO of Dense Air said:

“AutoAir at Millbrook is one of the most ambitious 5G Testbeds and Trials sites in the world. AutoAir is directly tackling the key 5G technology and system design challenges that CAVs create. The project has now completed the deployment of a hyper-dense small cell network that delivers ultra-high capacities which enables a range of new CAV use cases to be explored. Everyone in AutoAir consortium is excited to have reached this important milestone.”

Brendan O’Reilly, CTO at Telefónica UK, said:

“The AutoAir project is a great demonstration of how partnerships can help shape the use cases and drive the benefits that we all want to see from 5G. Test networks at sites like Millbrook will be crucial in understanding how 5G will enable the development of connected and autonomous vehicles as well as the associated business and consumer use cases which will transform the automotive sector.”

About AutoAir

The AutoAir project is a consortium of partners led by Airspan Networks and is hosted at Millbrook. It is a unique, accelerated development programme for 5G technology and is based on small cells that operate on a “Neutral Host” basis. The shared neutral host platform allows multiple public and private mobile operators to simultaneously use the same infrastructure through network slicing, which can radically improve the economics for 5G networks.

Other partners in the AutoAir consortium are Blu Wireless Technology, McLaren Applied Technologies, the 5G Innovation Centre at the University of Surrey, Dense Air, Real Wireless, Quortus and Celestia Technologies Group.

About Airspan

Airspan is a multi-award winning 4G & 5G network densification solution provider with an expansive product portfolio of indoor and outdoor, compact Femto, Pico, Micro and Macro base stations. The perfect tool kit to exploit the full potential of technologies such as mmWave, Sub 6GHz, Massive MIMO and open V-RAN architectures. As well as an industry leading fixed wireless access and backhaul solution portfolio for PTP and PTMP applications.

About Dense Air

Dense Air is headquartered in London, UK and has offices in the target launch markets of Ireland, Belgium and Portugal. Dense Air provides a unique “carrier of carriers” neutral host small cell services to deliver cost-effective densification to existing LTE mobile carriers or service providers. Dense Air is conducting extensive trials and proof-of-concepts in 2018 and will offer commercial services in 2019, including in the recently acquired spectrum in New Zealand, and plans to offer 5G services in Australia in 2020.

Contact information

Airspan Air Media:
Damiano Coletti (mediarelations@airspan.com)

Dense Air Media:
Paul Coffey (media@denseair.net)
Tel: +44 (0) 1895 467100

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

FDA Approves OTEZLA® (apremilast) for the Treatment of Oral Ulcers Associated with Behçet’s Disease19.7.2019 17:59:00 CESTPress release

Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has approved OTEZLA® (apremilast) 30 mg twice daily (BID) for the treatment of adult patients with oral ulcers associated with Behçet’s Disease. OTEZLA, an oral, selective inhibitor of phosphodiesterase 4 (PDE4), is the first and only approved treatment option for oral ulcers associated with Behçet’s Disease, a rare, chronic, multisystem inflammatory disease that is difficult to treat. “Oral ulcers are a recurring and debilitating manifestation that affects nearly everyone living with Behçet’s Disease, and have an important negative impact on the quality of life for these patients,” said Yusuf Yazici, M.D., Clinical Associate Professor, Department of Medicine, New York University Langone Health. “In the clinical trial, OTEZLA demonstrated improvements in measures of oral ulcers at week 12. OTEZLA has the potential to be a needed treatment option for U.S. patients and their physicians, who

Abiraterone Acetate Included in World Health Organisation’s Essential Medicines List for the Treatment of Metastatic Castration-Resistant Prostate Cancer19.7.2019 13:05:00 CESTPress release

The Janssen Pharmaceutical Companies of Johnson & Johnson is delighted with the recent announcement from the World Health Organisation (WHO) to include abiraterone acetate (ZYTIGA ® ) for the treatment of metastatic castration-resistant prostate cancer (mCRPC), in the updated Essential Medicines List, published on 9th July 2019.1,2 The WHO’s Essential Medicines List is a core guidance document that helps countries prioritise critical health products that are recommended to be widely available and affordable throughout health systems.1 “The inclusion of abiraterone acetate in the WHO Essential Medicines List highlights the critical role that this treatment can play in improving the lives of patients living with mCRPC and their families,” said Dr. Joaquín Casariego, Janssen Therapeutic Area Lead Oncology for Europe, Middle East & Africa, Janssen-Cilag S.A. “I am proud that we are working hard to impact survival and quality of life by developing and providing innovative medicines which ar

Gilead Sciences Licenses Respiratory and Herpes Antiviral Research Programs From Novartis19.7.2019 12:30:00 CESTPress release

Gilead Sciences, Inc. (NASDAQ: GILD) announced today that it has licensed three preclinical antiviral programs from Novartis, including investigational agents with the potential to treat human rhinovirus, influenza and herpes viruses. Under the agreement, Gilead will acquire exclusive global rights to develop and commercialize novel small molecules against three undisclosed targets. Novartis will receive an upfront payment and is eligible to receive up to an additional $291 million in potential milestone payments upon achievement of certain development and commercial milestones, as well as royalties on annual net sales. “Today’s announcement builds on Gilead’s heritage in antiviral research and development. We look forward to applying this expertise to advance the development of potential new treatments for viruses with limited therapeutic options,” said John McHutchison AO, MD, Gilead’s Chief Scientific Officer and Head of Research and Development. Gilead’s antiviral portfolio include

Schlumberger Announces Second-Quarter 2019 Results19.7.2019 11:00:00 CESTPress release

Schlumberger Limited (NYSE: SLB) today reported results for the second quarter of 2019. (Stated in millions, except per share amounts) Three Months Ended Change Jun. 30, 2019 Mar. 31, 2019 Jun. 30, 2018 Sequential Year-on-year Revenue $8,269 $7,879 $8,303 5% 0% Pretax segment operating income $968 $908 $1,094 7% -12% Pretax segment operating margin 11.7% 11.5% 13.2% 17 bps -148 bps Net income - GAAP basis $492 $421 $430 17% 14% Net income, excluding charges & credits* $492 $421 $594 17% -17% Diluted EPS - GAAP basis $0.35 $0.30 $0.31 17% 13% Diluted EPS, excluding charges & credits* $0.35 $0.30 $0.43 17% -19% North America revenue $2,801 $2,738 $3,139 2% -11% International revenue $5,463 $5,037 $5,065 8% 8% North America revenue, excluding Cameron $2,243 $2,178 $2,546 3% -12% International revenue, excluding Cameron $4,761 $4,469 $4,387 7% 9% *These are non-GAAP financial measures. See section titled "Charges & Credits" for details. Schlumberger Chairman and CEO Paal Kibsgaard commente

Schlumberger Appoints Olivier Le Peuch as CEO19.7.2019 10:46:00 CESTPress release

Schlumberger Limited (NYSE: SLB) announced today that its Board of Directors has appointed Olivier Le Peuch as its Chief Executive Officer and member of the Schlumberger Board, effective August 1, 2019. Mr. Le Peuch succeeds Paal Kibsgaard, who will retire as Chief Executive Officer effective that same date. Also effective August 1, Mr. Kibsgaard will step down as Chairman of the Board and retire as a member of the Board of Directors. Mr. Kibsgaard will retire after more than 22 years of service to the Company, including eight years as CEO and four years as Chairman. Effective the same date, Mark G. Papa, a current non-independent director, will become non-executive Chairman of the Board. Peter Currie will continue to serve as the Board’s Lead Independent Director. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190719005161/en/ Olivier Le Peuch is appointed Chief Executive Officer and a member of the Schlumberger Board, effe

Fluke Corporation Acquires Industrial Reliability Leader PRÜFTECHNIK19.7.2019 10:00:00 CESTPress release

Fluke Corp., the global leader in test and measurement instruments, has acquired Ismaning, Germany-based PRÜFTECHNIK, a market leader in precision laser shaft alignment, condition monitoring, and non-destructive testing. “Fluke’s acquisition of PRÜFTECHNIK reflects the growing importance our customers place on reliability systems to keep their equipment in optimum operating condition,” said Marc Tremblay, president of Fluke Corporation. “This business will help us usher in the next generation of solutions for our industrial customers.” Fluke Corporation For information on Fluke tools and applications, or to find the location of your nearest distributor, contact Fluke Corporation, P.O. Box 9090, Everett, WA USA 98206, call (800) 44-FLUKE (800-443-5853), fax (425) 446-5116, e-mail fluke-info@fluke.com or visit the Fluke Web site at http://www.fluke.com. About Fluke Founded in 1948, Fluke Corporation is the world leader in compact, professional electronic test tools and software for measu